BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36525936)

  • 1. The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity.
    Di Y; Jing X; Hu K; Wen X; Ye L; Zhang X; Qin J; Ye J; Lin R; Wang Z; He W
    Drug Resist Updat; 2023 Jan; 66():100909. PubMed ID: 36525936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophilin B induces chemoresistance by degrading wild-type p53 via interaction with MDM2 in colorectal cancer.
    Choi TG; Nguyen MN; Kim J; Jo YH; Jang M; Nguyen NNY; Yun HR; Choe W; Kang I; Ha J; Tang DG; Kim SS
    J Pathol; 2018 Sep; 246(1):115-126. PubMed ID: 29876924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA PiHL regulates p53 protein stability through GRWD1/RPL11/MDM2 axis in colorectal cancer.
    Deng X; Li S; Kong F; Ruan H; Xu X; Zhang X; Wu Z; Zhang L; Xu Y; Yuan H; Peng H; Yang D; Guan M
    Theranostics; 2020; 10(1):265-280. PubMed ID: 31903119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIRT1 promotes the progression and chemoresistance of colorectal cancer through the p53/miR-101/KPNA3 axis.
    Wang XW; Jiang YH; Ye W; Shao CF; Xie JJ; Li X
    Cancer Biol Ther; 2023 Dec; 24(1):2235770. PubMed ID: 37575080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
    Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
    EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
    Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The feedback loop of EFTUD2/c-MYC impedes chemotherapeutic efficacy by enhancing EFTUD2 transcription and stabilizing c-MYC protein in colorectal cancer.
    Zhu X; Li C; Gao Y; Zhang Q; Wang T; Zhou H; Bu F; Chen J; Mao X; He Y; Wu K; Li N; Luo H
    J Exp Clin Cancer Res; 2024 Jan; 43(1):7. PubMed ID: 38163859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer.
    Huang Y; Chan S; Chen S; Liu X; Li M; Zheng L; Dong Z; Yang Z; Liu Z; Zhou D; Zhang X; Zhang B
    J Transl Med; 2024 Feb; 22(1):133. PubMed ID: 38310229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAF-derived exosomal lncRNA FAL1 promotes chemoresistance to oxaliplatin by regulating autophagy in colorectal cancer.
    Zhu S; Mao J; Zhang X; Wang P; Zhou Y; Tong J; Peng H; Yang B; Fu Q
    Dig Liver Dis; 2024 Feb; 56(2):330-342. PubMed ID: 37400281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LUCAT1 promotes colorectal cancer tumorigenesis by targeting the ribosomal protein L40-MDM2-p53 pathway through binding with UBA52.
    Zhou Q; Hou Z; Zuo S; Zhou X; Feng Y; Sun Y; Yuan X
    Cancer Sci; 2019 Apr; 110(4):1194-1207. PubMed ID: 30690837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIR600HG suppresses metastasis and enhances oxaliplatin chemosensitivity by targeting ALDH1A3 in colorectal cancer.
    Yao Y; Li N
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32270866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
    Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
    Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factor B-MYB activates lncRNA CCAT1 and upregulates SOCS3 to promote chemoresistance in colorectal cancer.
    Liu F; Wang Y; Cao Y; Wu Z; Ma D; Cai J; Sha J; Chen Q
    Chem Biol Interact; 2023 Apr; 374():110412. PubMed ID: 36812959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXM1/DVL2/Snail axis drives metastasis and chemoresistance of colorectal cancer.
    Yang Y; Jiang H; Li W; Chen L; Zhu W; Xian Y; Han Z; Yin L; Liu Y; Wang Y; Pan K; Zhang K
    Aging (Albany NY); 2020 Dec; 12(23):24424-24440. PubMed ID: 33291076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-744 mediates the Oxaliplatin chemoresistance in colorectal cancer through inhibiting BIN1.
    Zhou Y; He A; Zhang L; Yi G
    Neoplasma; 2020 Mar; 67(2):296-303. PubMed ID: 31884801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
    Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIAA1549 promotes the development and chemoresistance of colorectal cancer by upregulating ERCC2.
    Ye F; Xie Y; Lin M; Liu Y; Fang Y; Chen K; Zhang Y; Ding Y
    Mol Cell Biochem; 2024 Mar; 479(3):629-642. PubMed ID: 37140813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin F
    Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
    World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.
    Azar MRMH; Aghazadeh H; Mohammed HN; Sara MRS; Hosseini A; Shomali N; Tamjidifar R; Tarzi S; Mansouri M; Sarand SP; Marofi F; Akbari M; Xu H; Shotorbani SS
    Int Immunopharmacol; 2021 Mar; 92():107355. PubMed ID: 33429333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
    Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
    Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.